Interaction Checker
No Interaction Expected
Bictegravir/ Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF)
Cyproterone acetate (50 mg and above)
Quality of Evidence: Very Low
Summary:
Coadministration has only been studied with cyproterone as feminizing hormone therapy (FHT) but based on metabolism and clearance a clinically significant interaction is unlikely when used for other indications. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cyproterone acetate is metabolized by CYP3A4 and does not inhibit CYPs when used at doses lower than 100 mg three times per day. Bictegravir is equally metabolized by CYP3A4 and UGT1A1 and does not inhibit or induce P450 enzymes. No interaction is expected with emtricitabine and tenofovir alafenamide. No significant pharmacokinetic interactions were observed when cyproterone was administered as feminizing hormone therapy (FHT) to trans women with HIV taking FHT and bictegravir/emtricitabine/tenofovir alafenamide.
Description:
View all available interactions with Bictegravir/ Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF) by clicking here.
Copyright © 2026 The University of Liverpool. All rights reserved.